The Academy of Managed Care Pharmacy (AMCP) is working with Congress to improve communication both in the pre- and post-approval settings between pharmaceutical companies and payers, according to Susan A. Cantrell, RPh, CAE, CEO of AMCP.
The Academy of Managed Care Pharmacy (AMCP) is working with Congress to improve communication both in the pre- and post-approval settings between pharmaceutical companies and payers, according to Susan A. Cantrell, RPh, CAE, CEO of AMCP.
Transcript
Are there any specific policy issues that AMCP would like to see change?
One important issues that AMCP has focused on for the last year is the ability or lack thereof of manufacturers and payers to communicate in 2 specific areas.
One is in the post-approval setting when you have a product on the market that has been approved, and the ability of the manufacturers to share healthcare economic information with formulary entities and other similar groups. In particular, the payer community. That relates to a law that was passed in 1997, Section 114 of the Food and Drug Administration Modernization Act (FDAMA), for which we only recently got guidance from the FDA in January of this year. So expanding and further clarifying FDAMA 114 is very important.
Equally important to AMCP members is the ability of pharmaceutical companies to be able to in a very specific and targeted way share information 12 to 18 months in advance of a product's approval with the payer community. With, of course, appropriate guide rails in place, to ensure there's not broad dissemination. But these conversations are important because health plans are doing forecasting, they're doing budgeting, they're doing rate setting, they're submitting their cost information to CMS well in advance of the beginning of a new plan year, and as we have new innovation coming to market, and in many cases expensive innovation, the plans need to be able to plan for it.
So allowing some very targeted communication in the pre-approval setting, we as an organization and our members feel is very important. So we're working with Congress right now to hopefully craft legislation to make that happen in the near future.
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More